Foresight or folly? Generics firms' foray into NCEs
Foresight or folly? Generics firms’ foray into NCEs
A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into new territory?
Comments are closed.